重症スギ花粉症成人および青年患者におけるオマリズマブの有効性と安全性に関する研究

基本情報

NCT ID

NCT03369704

ステータス

完了

試験のフェーズ

第3相

試験タイプ

介入

目標被験者数

337

治験依頼者名

Novartis

概要

The purpose of this study was to demonstrate the efficacy and safety of omalizumab compared with placebo, on top of SoC (anti-histamine and nasal corticosteroid) in adult and adolescent patients with severe Japanese cedar pollinosis, whose symptoms were inadequately controlled despite the current recommended therapies (nasal corticosteroids plus one or more medications out of anti-histamine, leukotriene receptor antagonist, or prostaglandin D2/thromboxane A2 receptor antagonist) in the previous 2 Japanese cedar pollen seasons.

対象疾患

介入

依頼者（Sponsor）